Literature DB >> 11445547

Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans.

K J Bame1.   

Abstract

Heparanases are endoglycosidases that cleave the heparan sulfate glycosaminoglycans from proteoglycan core proteins and degrade them to small oligosaccharides. Inside cells, these enzymes are important for the normal catabolism of heparan sulfate proteoglycans (HSPGs), generating glycosaminoglycan fragments that are then transported to lysosomes and completely degraded. When secreted, heparanases are thought to degrade basement membrane HSPGs at sites of injury or inflammation, allowing extravasion of immune cells into nonvascular spaces and releasing factors that regulate cell proliferation and angiogenesis. Heparanases have been described in a wide variety of tissues and cells, but because of difficulties in developing simple assays to follow activity, very little has been known about enzyme diversity until recently. Within the last 10 years, heparanases have been purified from platelets, placenta, and Chinese hamster ovary cells. Characterization of the enzymes suggests there may be a family of heparanase proteins with different substrate specificities and potential functions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445547     DOI: 10.1093/glycob/11.6.91r

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  37 in total

1.  A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils.

Authors:  Sara Massena; Gustaf Christoffersson; Elina Hjertström; Eyal Zcharia; Israel Vlodavsky; Nora Ausmees; Charlotte Rolny; Jin-Ping Li; Mia Phillipson
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

Review 2.  A starting place for the road to function.

Authors:  Jeremiah E Silbert; Geetha Sugumaran
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

Review 3.  Endovascular laser–tissue interactions and biological responses in relation to endovenous laser therapy.

Authors:  Michal Heger; Rowan F van Golen; Mans Broekgaarden; Renate R van den Bos; H A Martino Neumann; Thomas M van Gulik; Martin J C van Gemert
Journal:  Lasers Med Sci       Date:  2014-03       Impact factor: 3.161

4.  Guanidinylated neomycin mediates heparan sulfate-dependent transport of active enzymes to lysosomes.

Authors:  Stéphane Sarrazin; Beth Wilson; William S Sly; Yitzhak Tor; Jeffrey D Esko
Journal:  Mol Ther       Date:  2010-05-04       Impact factor: 11.454

5.  Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth.

Authors:  Udayan Bhattacharya; Lilach Gutter-Kapon; Tal Kan; Ilanit Boyango; Uri Barash; Shi-Ming Yang; JingJing Liu; Miriam Gross-Cohen; Ralph D Sanderson; Yuval Shaked; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Res       Date:  2019-11-05       Impact factor: 12.701

6.  Basic FGF mediates an immediate response of articular cartilage to mechanical injury.

Authors:  Tonia Vincent; Monika Hermansson; Mark Bolton; Robin Wait; Jeremy Saklatvala
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 7.  Heparan sulfate proteoglycans and their binding proteins in embryo implantation and placentation.

Authors:  Catherine B Kirn-Safran; Sonia S D'Souza; Daniel D Carson
Journal:  Semin Cell Dev Biol       Date:  2007-07-31       Impact factor: 7.727

8.  Rat and human HARE/stabilin-2 are clearance receptors for high- and low-molecular-weight heparins.

Authors:  Edward N Harris; Bruce A Baggenstoss; Paul H Weigel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-09       Impact factor: 4.052

9.  Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation.

Authors:  A J Brown; M Alicknavitch; S S D'Souza; T Daikoku; C B Kirn-Safran; D Marchetti; D D Carson; M C Farach-Carson
Journal:  Bone       Date:  2008-06-06       Impact factor: 4.398

10.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.